Page 85 - I. Chemical biology and drug discovery

Production process development of an Engineered EGF (Epidermal growth factor) protein
Young-Jae Jeon , Hyun-Tak Jin , Yun-Sik Choi 1
1
2
1 Research Institute, SLBiGen, Inc., Yeonsu-gu, Incheon, Korea
2 Research Institute, ProGen, Inc., Seongnam-si, Gyeonggi-do, Korea
BACKGROUND & AIM

EGF (epidermal growth factor) was generally known to be one of
the major factors for maintaining the skin homeostasis and
recovering injured states of skin. Therefore, recombinant human
EGF have for a long time been applied to cosmetics or medical
device for improving skin conditions. However, there are still a few
limitations for EGF to be used with an expected efficacy in vivo, in
which recombinant human EGF is known to be not stable in a
solution and its commercial price is relatively very expensive. To
solve these limitations, we made a cell line expressing the
engineering EGF (EGF-hyFc).

RESULTS

Here, we showed that production process development of EGF-hyFc
was successfully finished with ≥3.0g/L culture productivity and ≥65% of Figure 4. EGF-hyFc_ In vitro biological activity
purification yield. And also EGF-hyFc was stable in a severe
temperature condition of 40ºC when incubated more than 3 months.

Figure 5. EGF-hyFc_ Long-term In vitro biological activity in a severe
condition

Figure. 1. Cell line development A. Schematic view of EGF-hyFc. B. Figure 6. EGF-hyFc_ Long-term stability test in storage condition (-
MTX selection_ Productivity of 3-day culture supernatant. C. Long-term
stability of a candidate cell line 75~ 85oC)
CONCLUSION
Two main limitations, Instability in a solution and relatively high
production cost, of EGF for being used as an effective ingredient for
improving skin conditions and recovering injured states of skin need
to be solved. Here, our data showed that EGF-hyFc, an engineering
EGF, is very stable in a severe condition of 40℃ when incubated
more than three months. Also, production process development of
EGF-hyFc in bioreactor was successfully developed in which the
culture productivity was ≥3.0g/L and the purification yield was ≥
65%. Also, our data showed that the purity of EGF-hyFc was stable
more than 12 month in storage condition.
Figure. 2. Process Development for Bioreactor Culture. A. Viable Cell
Density B. Cell Viability C. Productivity (g/L) REFERENCES

Harris, R.C. et al. (2003) Exp. Cell Res. 284:2.
Jorissen, R.N. et al. (2003) Exp. Cell Res. 284:31.
Tripathi, N.K. and Shrivastava, A (2019) Front. Bioeng. Biotechnol. 7: 420.
Barnes. L.M et al. (2003) Front. Bioeng. Biotechnol. 81(6):631-9.
ACKNOWLEDGEMENTS Contact
This work was carried out with the support of information
“Cooperative Research Program for Agriculture
Science & Technology Development (Project title: Young-Jae Jeon:
Development and verification of quality analysis yjjeon@slbigen.com
methods for engineering EGF protein, Project No.
Figure. 3. Process Development of EGF-hyFc for Protein Purification. A. PJ013319022020)” Rural Development Yun-sik Choi:
SDS-PAGE. B. SE-HPLC. C. Purification Recovery Administration, Republic of Korea. yschoi@slbigen.com